Corvus Pharmaceuticals Statistics
Total Valuation
CRVS has a market cap or net worth of $135.11 million. The enterprise value is $114.02 million.
| Market Cap | 135.11M |
| Enterprise Value | 114.02M |
Important Dates
The last earnings date was Monday, May 6, 2024, after market close.
| Earnings Date | May 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CRVS has 62.55 million shares outstanding. The number of shares has increased by 5.33% in one year.
| Shares Outstanding | 62.55M |
| Shares Change (YoY) | +5.33% |
| Shares Change (QoQ) | -0.02% |
| Owned by Insiders (%) | 4.02% |
| Owned by Institutions (%) | 45.07% |
| Float | 37.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.05 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.40, with a Debt / Equity ratio of 0.03.
| Current Ratio | 3.40 |
| Quick Ratio | 3.30 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -60.00% and return on invested capital (ROIC) is -67.10%.
| Return on Equity (ROE) | -60.00% |
| Return on Assets (ROA) | -50.80% |
| Return on Capital (ROIC) | -67.10% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$887,750 |
| Employee Count | 28 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.95% in the last 52 weeks. The beta is 1.05, so CRVS's price volatility has been similar to the market average.
| Beta (1Y) | 1.05 |
| 52-Week Price Change | -28.95% |
| 50-Day Moving Average | 1.81 |
| 200-Day Moving Average | 1.79 |
| Relative Strength Index (RSI) | 59.75 |
| Average Volume (30 Days) | 248,698 |
Short Selling Information
The latest short interest is 1.29 million, so 2.06% of the outstanding shares have been sold short.
| Short Interest | 1.29M |
| Short Previous Month | 1.36M |
| Short % of Shares Out | 2.06% |
| Short % of Float | 3.40% |
| Short Ratio (days to cover) | 4.27 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -23.09M |
| Pretax Income | -24.86M |
| Net Income | -24.86M |
| EBITDA | -24.74M |
| EBIT | -24.86M |
| Earnings Per Share (EPS) | -$0.51 |
Balance Sheet
The company has $22.13 million in cash and $1.04 million in debt, giving a net cash position of $21.09 million or $0.34 per share.
| Cash & Cash Equivalents | 22.13M |
| Total Debt | 1.04M |
| Net Cash | 21.09M |
| Net Cash Per Share | $0.34 |
| Equity / Book Value | 33.36M |
| Book Value Per Share | 0.53 |
| Working Capital | 16.13M |
Cash Flow
| Operating Cash Flow | -20.98M |
| Capital Expenditures | n/a |
| Free Cash Flow | -20.98M |
| FCF Per Share | -$0.43 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CRVS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.33% |
| Shareholder Yield | -5.33% |
| Earnings Yield | -18.40% |
| FCF Yield | -15.53% |
Analyst Forecast
The average price target for CRVS is $6.25, which is 189.35% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.25 |
| Price Target Difference | 189.35% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -5.90% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |